Loading
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Latest quote
$112.75
−$0.69 · -0.61%
After-hours
$113
+$0.25 · +0.22%
Oct 8, 4:46 PM ET
Regular session · ET · Market data may be delayed.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Day range
Current $112.75
52-week range
Current $112.75
Regular session · ET · Market data may be delayed.
GoAI Score
Buy
Valuation
97
Deep Value
Sentiment
73
Bullish
Risk
29
Moderate Risk
Momentum
62
Gaining
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates. Among its clinical-stage assets are ruxolitinib, targeting steroid-refractory chronic graft-versus-host disease (GVHD), and itacitinib, which is undergoing Phase II/III trials for newly diagnosed chronic GVHD. Pemigatinib is also being investigated for conditions such as bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and other tumor types. Further advancing its research, the company is developing Parsaclisib, currently in Phase II studies for follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma. Additionally, Retifanlimab is in Phase II development for multiple indications, including MSI-high endometrial cancer, Merkel cell carcinoma, anal cancer, and non-small cell lung cancer. Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies, including key partners like Novartis International Pharmaceutical Ltd., Eli Lilly and Company, and Agenus Inc., among many others. These collaborations extend to clinical trials, notably joint efforts with MorphoSys AG and Xencor, Inc., to evaluate a combination therapy involving tafasitamab, plamotamab, and lenalidomide for patients with recurrent or resistant diffuse large B-cell lymphoma and follicular lymphoma. Established in 1991, the corporation's main offices are situated in Wilmington, Delaware.
Day range
Current $112.75
52-week range
Current $112.75
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 5.14B USD | 4.24B USD | 3.7B USD | 3.39B USD | 2.99B USD |
| Cost of goods sold | 372.1M USD | 312.1M USD | 254.99M USD | 207M USD | 150.99M USD |
| Gross profit | 4.77B USD | 3.93B USD | 3.44B USD | 3.19B USD | 2.84B USD |
| Research and development | 2.05B USD | 2.61B USD | 1.63B USD | 1.59B USD | 1.46B USD |
| Selling, general, and administrative | 1.38B USD | 1.22B USD | 1.16B USD | 1B USD | 739.56M USD |
| Operating expenses | 3.43B USD | 3.83B USD | 2.79B USD | 2.6B USD | 2.25B USD |
| Interest income | 105.6M USD | 128.71M USD | — | — | — |
| Interest expense | 2.43M USD | 2.28M USD | 2.55M USD | 2.67M USD | 1.91M USD |
| Depreciation and amortization | 93.29M USD | 89.25M USD | 82.66M USD | 67.86M USD | 57.84M USD |
| Operating income | 1.34B USD | 101.29M USD | 655.36M USD | 591.63M USD | 585.78M USD |
| Net income | 1.29B USD | 32.62M USD | 597.6M USD | 340.66M USD | 948.58M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Funds reporting this stock among their holdings, ordered by reported position size.
State Street SPDR S&P 500 ETF1557.T37.2B0.03%129.41T JPY0.09%¥122,700-0.57%
Vanguard Morningstar Total Stock Market ETFVTI665.58M0.03%2.3T USD0.03%$379.56-0.39%
Vanguard S&P 500 ETFVOO549.22M0.03%1.8T USD0.03%$711.28-0.43%
Vanguard Morningstar Small-Cap ETFVB481.46M0.26%185.3B USD0.03%$287.63+0.23%
Vanguard Morningstar Small-Cap Growth ETFVBK276.3M0.60%44.7B USD0.05%$340.59-0.48%
iShares Core S&P 500 ETFIVV257.02M0.03%899.63B USD0.03%$777.27-0.42%
State Street SPDR S&P 500 ETFSPY235.19M0.03%819.04B USD0.09%$773.93-0.42%
Invesco S&P 500 Equal Weight ETFRSP175.86M0.18%96.47B USD0.20%$211.87+0.60%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Growth ETFVBKiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYInvesco S&P 500 Equal Weight ETFRSPAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
